ArriVent BioPharma (AVBP) Operating Leases (2023 - 2026)

ArriVent BioPharma (AVBP) posted Operating Leases of $320000.0 for Q1 2026, up 2185.71% sequentially from $14000.0 in Q4 2024.

ArriVent BioPharma (AVBP) Operating Leases (2023 - 2026) Analysis & Trends

ArriVent BioPharma has reported Operating Leases for 3 years, with the latest figure at $320000.0 in Q1 2026.

Quarterly Operating Leases changed N/A year-over-year to $320000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $320000.0 (changed N/A YoY) and the FY2024 annual result came in at $14000.0, down 92.09% from the prior year.
Operating Leases grew to $320000.0 in Q1 2026 per AVBP's latest filing, from $14000.0 in the prior quarter.
Over five years, Operating Leases peaked at $320000.0 in Q1 2026 and troughed at $14000.0 in Q4 2024.
A 3-year average of $133833.3 and a median of $118000.0 in 2024 frame the typical range for Operating Leases.
The widest YoY moves for Operating Leases: up 92.09% in 2024, down 92.09% in 2024.
Over 3 years, Operating Leases stood at $177000.0 in 2023, then plunged by 92.09% to $14000.0 in 2024, then jumped by 2185.71% to $320000.0 in 2026.
According to Business Quant data, Operating Leases over the past three periods registered $320000.0, $14000.0, and $56000.0 for Q1 2026, Q4 2024, and Q3 2024 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	ArriVent BioPharma	1.43 Bn	1.43 Bn	-

Download Data